Data as of Oct 24
| +0.88 / +1.16%|
The 9 analysts offering 12-month price forecasts for Synageva BioPharma Corp have a median target of 113.00, with a high estimate of 126.00 and a low estimate of 75.00. The median estimate represents a +46.81% increase from the last price of 76.97.
The current consensus among 10 polled investment analysts is to Buy stock in Synageva BioPharma Corp. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.